Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen, Medarex, Oxford Genome Sciences Ltd. deal

MEDX will receive an undisclosed milestone payment from AMGN triggered by AMGN starting clinical trials of an undisclosed

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE